1. Guest, the 'News in Brief' for the week beginning 13th March 2023 is here.
    Dismiss Notice
  2. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Development of surrogate end-point biomarkers for chronic fatigue and myalgic encephalmyelitis/chronic fatigue syndrome (ME/CFS)

Discussion in 'ME/CFS research' started by strategist, Nov 11, 2017.

  1. strategist

    strategist Senior Member (Voting Rights)

    Watanabe et al. have received funding to conduct a 120 participants PET brain imaging study.

    The primary outcome:
    Secondary outcomes:
    Details here https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033257

    This group has previously published a ME/CFS neuroinflammation paper: https://www.ncbi.nlm.nih.gov/pubmed/24665088
    Inara, healthforall, Joel and 14 others like this.
  2. Esther12

    Esther12 Senior Member (Voting Rights)

    Inara, Joel and Valentijn like this.
  3. JaimeS

    JaimeS Senior Member (Voting Rights)

    Stanford, CA
    I was wondering if we were ever going to see a follow-up on this one! Awesome.
    Inara, Joel, Jan and 3 others like this.
  4. strategist

    strategist Senior Member (Voting Rights)

    If these brain scans cost $5000 (the figure given by Elzakker for his own study) then this is $600000 for scans alone. That's why we need government funding.

    However, crowdfunding by patients can help researchers make pilot studies that then enable big government funded studies like this one.
  5. Simon M

    Simon M Senior Member (Voting Rights)

    This has me slightly mystified, but looks like a large-scale replicatioin of the brain neuroinflammation study that caused such a stir back in 2014: First Direct Evidence of Neuroinflammation – ‘Encephalitis’ – in ME/CFS

    120 is an enormous sample size for a PET study - a good thing but also makes it expensive. So this study could be huge for linking mecfs to neuroinflammation (activation of the brain's immune system).

    The surprise, for me, is that the 2014 paper study said a replication was under way using a better marker of inflammation but we'd not heard anything since. And the stated purpose of this study isn't a replication, but to validate secondary end-points.

    "End-points" also suggests some kind of clinical trial, but there's no methodology. So this is intriguing and potentially very exciting, but we are still largely in the dark.
    Last edited: Nov 12, 2017
    Hutan, Inara, healthforall and 8 others like this.

Share This Page